Clinical Focus
Business Focus
Spotlight
Subscribe
CE/CME
- CDC
- Heart Failure
- Cardiovascular Clinical Consult
- Adult Immunization
- Hepatic Disease
- Rare Disorders
- Pediatric Immunization
- Implementing The Topcon Ocular Telehealth Platform
- Weight Management
- Screening
- Monkeypox
- Guidelines
- Men's Health
- Psychiatry
- Allergy
- Nutrition
- Women's Health
- Cardiology
- Substance Use
- Pediatrics
- Kidney Disease
- Genetics
- Complimentary & Alternative Medicine
- Dermatology
- Endocrinology
- Oral Medicine
- Otorhinolaryngologic Diseases
- Pain
- Gastrointestinal Disorders
- Geriatrics
- Infection
- Musculoskeletal Disorders
- Obesity
- Rheumatology
- Technology
- Cancer
- Nephrology
- Anemia
- Neurology
- Pulmonology
7 Drugs Approved for Primary Care: Q2 2024
As another quarter rounds out, a new batch of drugs have been approved by the US Food and Drug Administration for conditions often seen in primary care - quite a few of them first-in-class or novel in another way. For example, the first and only pneumococcal vaccine formulated specifically to protect adults 50 years and older; the first mRNA vaccine against RSV for adults aged 60 years and older; and the first inhaled product with a novel mechanism of action approved for maintenance chronic obstructive pulmonary disease (COPD) treatment in over 20 years. In the slides below, we recap these drugs and 5 more.
Missed last quarter's drug roundup? Check out 7 Drugs Approved for Primary Care: Q1 2024
Recent Videos
Related Content
